Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute
In summary, the overall approach to the treatment of neutropenic cancer patients is to bridge the neutropenic gap. Empirical therapy serves as an important pillar of support, and a rational programme for modifications of the initial therapy, according to the evolving clinical course of the patient,...
Gespeichert in:
| Veröffentlicht in: | The Journal of hospital infection 1990-04, Vol.15, p.41-48 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 48 |
|---|---|
| container_issue | |
| container_start_page | 41 |
| container_title | The Journal of hospital infection |
| container_volume | 15 |
| creator | Pizzo, P.A. |
| description | In summary, the overall approach to the treatment of neutropenic cancer patients is to bridge the neutropenic gap. Empirical therapy serves as an important pillar of support, and a rational programme for modifications of the initial therapy, according to the evolving clinical course of the patient, forms another pillar in bridging this gap (
Pizzo & Meyers, 1989). The incorporation of biologicals that might shorten the duration of neutropenia could potentially lead to greater improvements in outcome and greater success for therapy for the febrile neutropenic cancer patient. |
| doi_str_mv | 10.1016/0195-6701(90)90078-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79796081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0195670190900783</els_id><sourcerecordid>79796081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-45fb98bff3023d1eeb0a030f40a59ed5d9065e4cffe89aa5cba27695bc9ef5e13</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EKtvCG1DJJ9QeAuN1nKw5VKpWtFSq4AJny3HG4Cqxg-1U4il4ZZzNqtx6sjTz_WPNN4S8Y_CBAWs-ApOialpgFxIuJUC7q_gLsmGCb6ut5PIl2Twhr8lpSg8AUOrihJww2bKmrjfk736OEX2mLqUZE3We5l9Itc-ucyE7Q6foRh3_0FF7_RPHhQ32AFnsohuQepxzDBP6QhvtDUY66ewK-YlqOmFME5rsHksihvEQ_Vr6weuB7lf-zqfs8pzxDXll9ZDw7fE9Iz9uPn_ff6nuv93e7a_vK8NFm6ta2E7uOms5bHnPEDvQwMHWoIXEXvQSGoG1sRZ3UmthOr1tGyk6I9EKZPyMvF_nTjH8LotnNbpkcBi0xzAn1cpWNrBbwHoFTQwpRbTqKEQxUMsd1CJZLZKVBHW4g-Ildn6cP3cj9v9Dq_jSv1r7WJZ8dBhVMsWYwd7FIkv1wT3_wT8Q85tR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79796081</pqid></control><display><type>article</type><title>Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Pizzo, P.A.</creator><creatorcontrib>Pizzo, P.A.</creatorcontrib><description>In summary, the overall approach to the treatment of neutropenic cancer patients is to bridge the neutropenic gap. Empirical therapy serves as an important pillar of support, and a rational programme for modifications of the initial therapy, according to the evolving clinical course of the patient, forms another pillar in bridging this gap (
Pizzo & Meyers, 1989). The incorporation of biologicals that might shorten the duration of neutropenia could potentially lead to greater improvements in outcome and greater success for therapy for the febrile neutropenic cancer patient.</description><identifier>ISSN: 0195-6701</identifier><identifier>EISSN: 1532-2939</identifier><identifier>DOI: 10.1016/0195-6701(90)90078-3</identifier><identifier>PMID: 1971644</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Agranulocytosis - complications ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - therapeutic use ; Drug Therapy, Combination ; Fever - drug therapy ; Fever - etiology ; Humans ; Neoplasms - complications ; Neutropenia - complications ; Neutropenia - etiology ; Randomized Controlled Trials as Topic</subject><ispartof>The Journal of hospital infection, 1990-04, Vol.15, p.41-48</ispartof><rights>1990</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-45fb98bff3023d1eeb0a030f40a59ed5d9065e4cffe89aa5cba27695bc9ef5e13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0195-6701(90)90078-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1971644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pizzo, P.A.</creatorcontrib><title>Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute</title><title>The Journal of hospital infection</title><addtitle>J Hosp Infect</addtitle><description>In summary, the overall approach to the treatment of neutropenic cancer patients is to bridge the neutropenic gap. Empirical therapy serves as an important pillar of support, and a rational programme for modifications of the initial therapy, according to the evolving clinical course of the patient, forms another pillar in bridging this gap (
Pizzo & Meyers, 1989). The incorporation of biologicals that might shorten the duration of neutropenia could potentially lead to greater improvements in outcome and greater success for therapy for the febrile neutropenic cancer patient.</description><subject>Agranulocytosis - complications</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Fever - drug therapy</subject><subject>Fever - etiology</subject><subject>Humans</subject><subject>Neoplasms - complications</subject><subject>Neutropenia - complications</subject><subject>Neutropenia - etiology</subject><subject>Randomized Controlled Trials as Topic</subject><issn>0195-6701</issn><issn>1532-2939</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EKtvCG1DJJ9QeAuN1nKw5VKpWtFSq4AJny3HG4Cqxg-1U4il4ZZzNqtx6sjTz_WPNN4S8Y_CBAWs-ApOialpgFxIuJUC7q_gLsmGCb6ut5PIl2Twhr8lpSg8AUOrihJww2bKmrjfk736OEX2mLqUZE3We5l9Itc-ucyE7Q6foRh3_0FF7_RPHhQ32AFnsohuQepxzDBP6QhvtDUY66ewK-YlqOmFME5rsHksihvEQ_Vr6weuB7lf-zqfs8pzxDXll9ZDw7fE9Iz9uPn_ff6nuv93e7a_vK8NFm6ta2E7uOms5bHnPEDvQwMHWoIXEXvQSGoG1sRZ3UmthOr1tGyk6I9EKZPyMvF_nTjH8LotnNbpkcBi0xzAn1cpWNrBbwHoFTQwpRbTqKEQxUMsd1CJZLZKVBHW4g-Ildn6cP3cj9v9Dq_jSv1r7WJZ8dBhVMsWYwd7FIkv1wT3_wT8Q85tR</recordid><startdate>19900401</startdate><enddate>19900401</enddate><creator>Pizzo, P.A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900401</creationdate><title>Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute</title><author>Pizzo, P.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-45fb98bff3023d1eeb0a030f40a59ed5d9065e4cffe89aa5cba27695bc9ef5e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Agranulocytosis - complications</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Fever - drug therapy</topic><topic>Fever - etiology</topic><topic>Humans</topic><topic>Neoplasms - complications</topic><topic>Neutropenia - complications</topic><topic>Neutropenia - etiology</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pizzo, P.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of hospital infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pizzo, P.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute</atitle><jtitle>The Journal of hospital infection</jtitle><addtitle>J Hosp Infect</addtitle><date>1990-04-01</date><risdate>1990</risdate><volume>15</volume><spage>41</spage><epage>48</epage><pages>41-48</pages><issn>0195-6701</issn><eissn>1532-2939</eissn><abstract>In summary, the overall approach to the treatment of neutropenic cancer patients is to bridge the neutropenic gap. Empirical therapy serves as an important pillar of support, and a rational programme for modifications of the initial therapy, according to the evolving clinical course of the patient, forms another pillar in bridging this gap (
Pizzo & Meyers, 1989). The incorporation of biologicals that might shorten the duration of neutropenia could potentially lead to greater improvements in outcome and greater success for therapy for the febrile neutropenic cancer patient.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>1971644</pmid><doi>10.1016/0195-6701(90)90078-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-6701 |
| ispartof | The Journal of hospital infection, 1990-04, Vol.15, p.41-48 |
| issn | 0195-6701 1532-2939 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79796081 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Agranulocytosis - complications Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Drug Therapy, Combination Fever - drug therapy Fever - etiology Humans Neoplasms - complications Neutropenia - complications Neutropenia - etiology Randomized Controlled Trials as Topic |
| title | Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A38%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20issues%20in%20the%20antibiotic%20primary%20management%20of%20the%20febrile%20neutropenic%20cancer%20patient:%20a%20perspective%20from%20the%20National%20Cancer%20Institute&rft.jtitle=The%20Journal%20of%20hospital%20infection&rft.au=Pizzo,%20P.A.&rft.date=1990-04-01&rft.volume=15&rft.spage=41&rft.epage=48&rft.pages=41-48&rft.issn=0195-6701&rft.eissn=1532-2939&rft_id=info:doi/10.1016/0195-6701(90)90078-3&rft_dat=%3Cproquest_cross%3E79796081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79796081&rft_id=info:pmid/1971644&rft_els_id=0195670190900783&rfr_iscdi=true |